Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NILOdeepR: Nilotinib in Newly Diagnosed Ph+ CML
NCT02546674Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Deep Molecular Response MR4.5 at 24 months. Started Feb 2016; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02546674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546674.